An interventional study of Adenosylcobalamin and Placebo in Malnutrition, sponsored by Fakultas Kedokteran Universitas Indonesia. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-13.
Sponsored by Fakultas Kedokteran Universitas Indonesia · Not applicable, Interventional, and Treatment
The trial is conducted to observe the effectiveness of cobamamide supplements in improving the clinical state malnourished patients.
1,277 studies on the registry are indexed under Malnutrition; 230 are open to participants now.
This study's planned enrollment of 124 is close to the median of 118 across 843 interventional studies indexed under Malnutrition.
Browse Malnutrition studies →Fakultas Kedokteran Universitas Indonesia is the lead sponsor of 36 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient is given Cobamamide 2 x 3000 mg for 28 days.
Drug: Adenosylcobalamin
The patient is given placebo 2 x 1 capsule for 28 days.
Drug: Placebo
The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
Also known as: Cobazim 3000
The drug doesn't contain any properties or substances for treatment.
Change of Appetite
Using the Council on Nutrition Appetite Questionnaire to evaluate the appettite changes
Time frame: 28 days
Nutritional Status
Using the Subjective Global Asssessment form to assess the changes in nutritional status
Time frame: 28 days
Bioimpendance Analysis Result
Changes in Muscle Mass
Time frame: 28 days
Vitamin B12 (1)
Serum B12 Level
Time frame: 28 days
Vitamin B12 (2)
Methylmalonic Acid Level
Time frame: 28 days
Pre-albumin
Prealbumin Level
Time frame: 28 days
Laboratory result (1)
Serum ureum and creatinine level
Time frame: 28 days
Laboratory result (2)
ALT and AST level
Time frame: 28 days
Laboratory result (3)
Complete Blood Count
Time frame: 28 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fakultas Kedokteran Universitas Indonesia